Inozyme Pharma(INZY) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Interim data from SEAPORT 1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track fo ...